Santen
Focus: Santen is a newly-established (2023) ophthalmology-focused biotechnology company headquartered in Emeryville, CA with an extensive clinical pipeline across dry eye, glaucoma, retinal diseases, and corneal conditions.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Open Jobs
71-5 this month
Cooling — net -5 jobs in 30d
21 added, 26 removed. Slower than typical.
Should You Work at Santen?
AI assessmentSanten is a high-risk, high-opportunity play for those willing to build something from the ground up in ophthalmology; best suited for early-career or mission-driven professionals comfortable with execution uncertainty.
Why Work Here
- Massive pipeline depth: 50 active trials across Phase 1-3 with 17 Phase 3 programs providing multiple near-term catalysts
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Declining
LOE Approaching
Legacy antibiotic asset approaching patent expiration with minimal differentiation.
Help build intelligence for Santen
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.